RxDoctor Payments Data

Larisa Karazhova

Family · Valley Village, CANPI 1144520388

Payments from drug & device makers

$10,218in general payments, 2019–2025

Across 451 payments — averaging $22.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$1K
  • AstraZeneca$873
  • Amarin Pharma, Inc.$442
  • Lilly USA, LLC$434
  • Bayer$395
  • plus $5K from 43 others

What the payments were for

  • Food & beverage$10,218100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,218 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$19,190
Medicare patients
58
Services billed
1,013

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate46$61,466
MounjaroTirzepatide52$55,626
Chlorzoxazone15$25,190
OzempicSemaglutide12$10,844
LinzessLinaclotide19$10,809
JanumetSitagliptin Phos/Metformin Hcl15$10,742
Fenofibrate11$7,753
Icosapent Ethyl33$4,845
VascepaIcosapent Ethyl13$3,582
Lidocaine16$2,578
Memantine Hcl ErMemantine Hcl18$2,227
Ibuprofen-FamotidineIbuprofen/Famotidine13$1,665
Triazolam14$593
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide28$445
Albuterol Sulfate HfaAlbuterol Sulfate14$333

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$434$55,62652 claims
Novo NordiskOzempic$290$10,84412 claims
AbbVieLinzess$1,786$10,80919 claims
MerckJanumet$177$10,74215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.

Other family in Valley Village

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →